Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

NCT01456078 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT01456078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01456078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
Lead sponsor
Lund University Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2018
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, neuroendocrine tumors